Department of Pediatrics and Adolescent Medicine

Head: Prof. dr. Klaus-Michael Debatin
Ulm University

Research at the

Department of Pediatrics and Adolescent Medicine

Contact

Research Management

Our Research

Our research in Hematology and Oncology is dedicated to understanding the role of cell death (apoptosis) and cell death signaling in diseases, such as cancer, with the aim of developing new therapies from this knowledge. 1996, 1990), while identifying and initially describing its role in cancer therapy in 1996. A particular focus on strategies to overcome treatment resistance in leukemia, neuroblastoma and brain tumors. In doing so, we have addressed several issues dealing with apoptosis regulators and apoptosis signaling as prognostic factors and therapeutic targets, and have contributed to the development of new drugs for cancer therapy. By using models of primary leukemias, we are in the process of analyzing aspects of leukemia stem cell function and apoptosis sensitivity of leukemia-initiating cells as well as parameters for treatment response and outcome in patients. The expertise of our work group has been introduced into the international study group (I-BMF) for the treatment of childhood leukemia. In the area of solid tumors, we investigate the molecular pathways which may provide novel therapeutic targets in glioblastoma by utilizing patient-derived tumor cells.

The Experimental Pediatric Oncology Section investigates the molecular pathogenesis and diagnosis of neuroblastoma and develops experimental therapy for neuroblastoma and acute lymphoblastic leukemia.

In the field of Non-malignant Hematological Diseases, we therefore investigate pathological processes and the underlying molecular alterations as a basis for the development of specific treatment strategies, especially in the area of congenital and acquired erythrocytoses / polycythemias, as well as rare metabolic defects associated with the disruption of hematopoiesis.

In the area of Stem cell transplantation and immunology, Our work groups have also received the genetic origins of several forms of severe combined immune defects (SCID). In the early seventies one of the first ever bone marrow transplants in children in Europe was performed at our hospital. Novel therapies, as haploidentical stem cell transplantations, cell-based immunotherapies and, most recently, radio-immunotherapy-based conditioning for reduced toxicity during treatment of severe combined immune defects, congenital hematological disorders and leukemias, have since been developed. The workgroup at Ulm University is part of the federal network on primary immunodeficiencies.

The research areas of the Division of Pediatric Endocrinology and Diabetes include development and disturbances of the endocrine system, endocrine Regulation of body weight and diabetes mellitus type 1 and type 2. The main focus of research projects is on diseases in obesity and lipodystrophy and their comorbidities. On the one hand the aim is to identify the underlying pathophysiology on the genetic, molecular, cellular, organ and systemic level. On the other hand, in clinical studies novel treatment options are evaluated.

The research of the Neonatology and Pediatric Intensive Care Section is dedicated to clinical studies related to primary care of neonates and preterm infants. Our center participates in a number of multicenter randomized trials, including the coordination of a European multicenter study on the use of inhaled NO treatment, and has initiated a study on permissive hypercapnia in very immature preterm infants.

In the Division of Social Pediatrics and Child Neurology, we study the developmental prognosis of neonates after severe perinatal asphyxia and the long-term prognosis of premature babies of very low birth weight. We are assessing the influence of longchain polyunsaturated fatty acids on characteristics and cognition in attention-deficit / hyperactivity disorder (ADHD). Finally, we study the long term development and outpatient care of children with ADHD.

Our research in the Hematology and oncology aims to understand the role of programmed cell death (apoptosis) and cell death pathways in diseases such as cancer, and thus to develop new therapies (see the DFG video on our cell death research on YouTube). The abnormal death of diseased cells is an important factor in the development and control of cancer. Our laboratory was involved in the early discovery of one of the central apoptotic signaling pathways (CD95 / APO / Fas) (1989, 1990). In 1996, in one of the first descriptions, our scientists identified the role of cell death signaling pathways in cancer therapy. A particular focus is on approaches to overcome therapy resistance in leukemias, neuroblastomas and brain tumors. We investigated various issues related to apoptosis regulators and apoptosis signaling pathways as factors for the assessment of treatment success and therapeutic targets, and contributed to the development of new drugs in cancer therapy. Using models of primary leukemias, we analyze aspects of the function of leukemia stem cells and the apoptosis sensitivity of leukemia-inducing cells as well as factors and factors influencing the success of treatment in patients. The expertise of our working group flows into the international study group (I-BMF) for the treatment of childhood leukemia. In the area of solid tumors, we are investigating the molecular mechanisms that characterize primary patient material as new therapeutic approaches in glioblastoma.

The Section Experimental Pediatric Oncology investigates the molecular pathogenesis as well as methods for the diagnosis of neuroblastomas and develops experimental therapies for neuroblastomas and acute lymphoblastic leukemias.

Also in the field of non-malignant, ie non-malignant hematological diseases we examine the processes of pathological changes and their underlying molecular causes. They may serve as a basis for targeted treatment, particularly in the area of congenital and acquired erythrocytosis / polycythemia (high red blood cell count), as well as in rare metabolic defects with hematopoietic disruption.

In the area Stem cell transplantation and immunology Our research groups have contributed significantly to the development of blood stem cell and bone marrow transplantation and have characterized the genetic basis of various types of severe combined immunodeficiencies (SCID). One of the first bone marrow transplantations of children in Europe was carried out at our clinic at the beginning of the 1970s. Since then, novel therapies such as haploid stem cell transplantation, cell-based immunotherapies and most recently radioimmunotherapy-based conditioning have been developed to reduce toxicity in the treatment of severe combined immunodeficiency, congenital hematologic disorders and leukemias. The working group at the University of Ulm coordinates the focus on severe combined immunodeficiency in the area of the German network of primary immunodeficiency diseases.

The research areas of Department of Pediatric Endocrinology and Diabetology include the development and disorders of the endocrine system, endocrine control of body weight and Diabetes mellitus Type 1 and Type 2. The main focus of our research projects is on diseases associated with changes in adipose tissue and its function, such as obesity, lipodystrophies and their comorbidities. On the one hand, the goal is to identify the underlying pathophysiology at the genetic, molecular, cellular, organ and systemic levels. On the other hand, treatment options are being tested in clinical trials.

The research of the Department of Neonatology and Pediatric Intensive Care Medicine is dedicated to clinical studies Primary care of newborns and premature births. Our center is involved in a number of randomized trials, including the co-ordination of a European multicenter study on the use of nitric oxide inhalation. In addition, a study was initiated to improve artificial respiration in very immature premature babies.

In the section Social pediatric center and pediatric neurology we examine the estimation of the future Development (prognosis) of newborns after severe respiratory arrest (asphyxia) and the long-term development of very small premature babies. We determine the influence of long-chain polyunsaturated fatty acids on course and perception (cognition) Attention Hyperactivity Disorder (ADHD) as well as in the long term care situation and development of children with ADHD.

Type 1 diabetes: current research approaches

Type 1 diabetes: current research approaches Why do people ever develop type 1 diabetes? Which circumstances contribute to the development? Are there any…
Pediatric rheumatism – tips for diagnosis and treatment

Pediatric rheumatism: causes, symptoms and treatment Childish rheumatism is the name given to at least six weeks of painful inflammatory disease of the…
Pediatric dentist herne »playful treatment in the pediatric dentistry clinic

Pediatric Dentistry Pediatric dentist in Herne Pediatric dentistry begins with the early check-up visit to the dentist To familiarize your child with the…
Pediatric Dentist berlin charlottenburg – – ku64

pediatric dentist Pediatric Dentist @ KU64 – Four Pediatric Dentists Ensure Healthy Teeth at K >The KU64 world of holistic child and adolescent…